Publication Date 1-1-2026 DOI 10.1371/journal.pone.0349130 PubMedCentral® Posted Date 5-14-2026 PubMedCentral® Full Text Version Post-print Abstract ARv7, the most prevalent androgen receptor (AR) variant in castration-resistant prostate cancer, lacks the ligand binding domain (LBD), rendering it resistant to LBD-targeted therapies. Identifying new therapeutic targets requires defining the coregulators and associated regulatory enzymes that govern AR and ARv7 transcriptional activity.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ross
Contact Ross, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack